Terms: = Bone cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874
259 results:
1. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Murdock HM; Ho VT; Garcia JS
Front Immunol; 2024; 15():1359113. PubMed ID: 38571944
[TBL] [Abstract] [Full Text] [Related]
2. A personalized medicine approach identifies enasidenib as an efficient treatment for idh2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract] [Full Text] [Related]
3. SMARCB1-Deficient Skull Base Chondrosarcoma with 12p Duplication Presenting as Somatic-Type Malignancy Arising from Metastatic Seminoma.
Argyris PP; Challa B; Satturwar S; VanKoevering KK; Wakely PE
Head Neck Pathol; 2024 Jan; 18(1):1. PubMed ID: 38236556
[TBL] [Abstract] [Full Text] [Related]
4. Tumor heterogeneity and tumor-microglia interactions in primary and recurrent idh1-mutant gliomas.
Blanco-Carmona E; Narayanan A; Hernandez I; Nieto JC; Elosua-Bayes M; Sun X; Schmidt C; Pamir N; Özduman K; Herold-Mende C; Pagani F; Cominelli M; Taranda J; Wick W; von Deimling A; Poliani PL; Rehli M; Schlesner M; Heyn H; Turcan Ş
Cell Rep Med; 2023 Nov; 4(11):101249. PubMed ID: 37883975
[TBL] [Abstract] [Full Text] [Related]
5. Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Shen X; Dong P; Kong J; Sun N; Wang F; Sang L; Xu Y; Zhang M; Chen X; Guo R; Wang S; Lin Q; Jiang Z; Xu S; Zhang C; Bian Z; Wang W; Guo R
Cell Biochem Funct; 2023 Dec; 41(8):1343-1356. PubMed ID: 37823726
[TBL] [Abstract] [Full Text] [Related]
6. idh mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
Setola E; Benini S; Righi A; Gamberi G; Carretta E; Ferrari C; Avnet S; Palmerini E; Magagnoli G; Gambarotti M; Lollini PL; Cesari M; Cocchi S; Paioli A; Longhi A; Scotlandi K; Laginestra MA; Donati DM; Baldini N; Ibrahim T
BMC Cancer; 2023 Sep; 23(1):907. PubMed ID: 37752419
[TBL] [Abstract] [Full Text] [Related]
7. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract] [Full Text] [Related]
8. Oncometabolite D-2-hydroxyglutarate-dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia.
Zhu X; Hao J; Zhang H; Chi M; Wang Y; Huang J; Xu R; Xincai Z; Xin B; Sun X; Zhang J; Zhou S; Cheng D; Yuan T; Ding J; Zheng S; Guo C; Yang Q
Commun Biol; 2023 Sep; 6(1):977. PubMed ID: 37741882
[TBL] [Abstract] [Full Text] [Related]
9. idh-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall.
Sekita T; Yoshida A; Kawai A; Ichikawa H; Kobayashi E
Genes Chromosomes Cancer; 2023 Dec; 62(12):755-760. PubMed ID: 37732625
[TBL] [Abstract] [Full Text] [Related]
10. Diagnosis- and Prognosis-Related Gene Alterations in
Morishita S; Komatsu N
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629188
[No Abstract] [Full Text] [Related]
11. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract] [Full Text] [Related]
12. Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
Borate U; Yang F; Press R; Ruppert AS; Jones D; Caruthers S; Zhao W; Vergilio JA; Pavlick DC; Juckett L; Norris B; Bucy T; Burd A; Stein EM; Patel P; Baer MR; Stock W; Schiller G; Blum W; Kovacsovics T; Litzow M; Foran J; Heerema NA; Rosenberg L; Marcus S; Yocum A; Stefanos M; Druker B; Byrd JC; Levine RL; Mims A
Blood Adv; 2023 Oct; 7(20):6048-6054. PubMed ID: 37459200
[TBL] [Abstract] [Full Text] [Related]
13. Concurrent high-grade glioma with cavernous malformations and pathogenic variants in PDCD10 and SMARCA4.
Glanz H; Damodharan SN; Smith-Simmer K; Helgager J; Puccetti D
Childs Nerv Syst; 2023 Nov; 39(11):3311-3315. PubMed ID: 37328659
[TBL] [Abstract] [Full Text] [Related]
14. A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.
Morris VS; Ghazi H; Fletcher DM; Guinn BA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298623
[TBL] [Abstract] [Full Text] [Related]
15. Characteristics and prognostic impact of idh mutations in AML: a COG, SWOG, and ECOG analysis.
Zarnegar-Lumley S; Alonzo TA; Gerbing RB; Othus M; Sun Z; Ries RE; Wang J; Leonti A; Kutny MA; Ostronoff F; Radich JP; Appelbaum FR; Pogosova-Agadjanyan EL; O'Dwyer K; Tallman MS; Litzow M; Atallah E; Cooper TM; Aplenc RA; Abdel-Wahab O; Gamis AS; Luger S; Erba H; Levine R; Kolb EA; Stirewalt DL; Meshinchi S; Tarlock K
Blood Adv; 2023 Oct; 7(19):5941-5953. PubMed ID: 37267439
[TBL] [Abstract] [Full Text] [Related]
16. Mutant idh regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract] [Full Text] [Related]
17. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V; Chawla SP; Conley AP; Wilky BA; Tolcher A; Lakhani NJ; Berz D; Andrianov V; Crago W; Holcomb M; Hussain A; Veldstra C; Kalabus J; O'Neill B; Senne L; Rowell E; Heidt AB; Willis KM; Eckelman BP
Clin Cancer Res; 2023 Aug; 29(16):2988-3003. PubMed ID: 37265425
[TBL] [Abstract] [Full Text] [Related]
18. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract] [Full Text] [Related]
19. [Second allogeneic (update). Guidelines from the Francophone Society of bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Yafour N; Couturier MA; Borel C; Charbonnier A; Coman T; Fayard A; Masouridi-Levrat S; Yakoub-Agha I; Roy J
Bull Cancer; 2024 Feb; 111(2S):S29-S39. PubMed ID: 37045732
[TBL] [Abstract] [Full Text] [Related]
20. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
[TBL] [Abstract] [Full Text] [Related]
[Next]